Written in October, 2020: Brilacidin is one of
Post# of 72447
(Total Views: 661)
Posted On: 08/05/2021 11:16:30 AM
Written in October, 2020 :
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of
for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis.
https://science.gmu.edu/news/innovation-pharm...ng-results
While Brilacidin, with an SI of 426, being intensely researched by GMU, a state-of-the-art laboratory with biosafety level 3 and aerosolization capabilities is stuck in the "queue" and languishes in the muck of political science, slide 16 of this FDA October 22, 2000 presentation reveals:
FDA Safety Surveillance of COVID-19 Vaccines :
DRAFT Working list of possible adverse event outcomes
***Subject to change***
Guillain-Barré syndrome
Acute disseminated encephalomyelitis
Transverse myelitis
Encephalitis/myelitis/encephalomyelitis/
meningoencephalitis/meningitis/
encepholapathy
Convulsions/seizures
Stroke
Narcolepsy and cataplexy
Anaphylaxis
Acute myocardial infarction
Myocarditis/pericarditis
Autoimmune disease
Deaths
Pregnancy and birth outcomes
Other acute demyelinating diseases
Non-anaphylactic allergic reactions
Thrombocytopenia
Disseminated intravascular coagulation
Venous thromboembolism
Arthritis and arthralgia/joint pain
Kawasaki disease
Multisystem Inflammatory Syndrome
in Children
Vaccine enhanced disease
https://www.fda.gov/media/143557/download
Brilacidin is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of
for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. https://science.gmu.edu/news/innovation-pharm...ng-results
While Brilacidin, with an SI of 426, being intensely researched by GMU, a state-of-the-art laboratory with biosafety level 3 and aerosolization capabilities is stuck in the "queue" and languishes in the muck of political science, slide 16 of this FDA October 22, 2000 presentation reveals:
FDA Safety Surveillance of COVID-19 Vaccines :
DRAFT Working list of possible adverse event outcomes
***Subject to change***
Guillain-Barré syndrome
Acute disseminated encephalomyelitis
Transverse myelitis
Encephalitis/myelitis/encephalomyelitis/
meningoencephalitis/meningitis/
encepholapathy
Convulsions/seizures
Stroke
Narcolepsy and cataplexy
Anaphylaxis
Acute myocardial infarction
Myocarditis/pericarditis
Autoimmune disease
Deaths
Pregnancy and birth outcomes
Other acute demyelinating diseases
Non-anaphylactic allergic reactions
Thrombocytopenia
Disseminated intravascular coagulation
Venous thromboembolism
Arthritis and arthralgia/joint pain
Kawasaki disease
Multisystem Inflammatory Syndrome
in Children
Vaccine enhanced disease
https://www.fda.gov/media/143557/download
(3)
(0)